Atazanavir contraindications: Difference between revisions
Jump to navigation
Jump to search
Created page with "==Contraindications== REYATAZ (atazanavir sulfate) is contraindicated: *in patients with previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson ..." |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Atazanavir}} | |||
{{CMG}}; {{AE}} {{MM}} | |||
==Contraindications== | ==Contraindications== | ||
REYATAZ (atazanavir sulfate) is contraindicated: | REYATAZ (atazanavir sulfate) is contraindicated: | ||
| Line 6: | Line 9: | ||
*when coadministered with drugs that are highly dependent on CYP3A or UGT1A1 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These and other contraindicated drugs are listed in Table 3.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [E.R. SQUIBB & SONS, L.L.C.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=165cff62-b284-4a27-a65d-9ec8a5bfcdd8#nlm34089-3 | publisher = | date = | accessdate}}</ref> | *when coadministered with drugs that are highly dependent on CYP3A or UGT1A1 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These and other contraindicated drugs are listed in Table 3.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [E.R. SQUIBB & SONS, L.L.C.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=165cff62-b284-4a27-a65d-9ec8a5bfcdd8#nlm34089-3 | publisher = | date = | accessdate}}</ref> | ||
[[File:Atazanavir contraindication.jpg]] | [[File:Atazanavir contraindication.jpg|750px]] | ||
Latest revision as of 18:57, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Contraindications
REYATAZ (atazanavir sulfate) is contraindicated:
- in patients with previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of this product.
- when coadministered with drugs that are highly dependent on CYP3A or UGT1A1 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These and other contraindicated drugs are listed in Table 3.[1]
References
- ↑ "REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [E.R. SQUIBB & SONS, L.L.C.]". Text " accessdate" ignored (help)
Adapted from the FDA Package Insert.